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Lysosomescyllo-Inositol (SI) is an endogenous inositol stereoisomer known to inhibit aggregation and ﬁbril formation
of the amyloid-beta peptide (Aβ). Human clinical trials using SI to treat Alzheimer disease (AD) patients have
shown potential beneﬁts. In light of the growing therapeutic potential of SI, the objective of our study was to
gain a more thorough understanding of the mechanism of action. In addition to Aβ plaques, a prominent
pathological feature of AD is the extensive accumulation of autophagic vacuoles (AVs) suggesting dysfunc-
tion in this degradation pathway. Using the TgCRND8 mouse model for AD, we examined SI treatment effects
on various components of the autophagic pathway. Autophagy impairment in TgCRND8 mice occurs in the
latter stages of the pathway where AV-lysosome fusion and lysosomal degradation take place. SI treatment
attenuated this impairment with a decrease in the size and the number of accumulated AVs. We propose
that the beneﬁcial effects of SI–Aβ interactions may resolve autophagic deﬁciencies in the AD brains.
Crown Copyright © 2012 Published by Elsevier B.V. All rights reserved.1. Introduction
scyllo-Inositol (SI) is an endogenous inositol stereoisomer present
in the brain [1,2]. Unlike myo-inositol, the predominant stereoisomer
in nature, SI is not directly involved in phosphatidylinositol signaling
pathways [3,4]. While its physiological role is unclear, SI has been
shown to bind amyloid-beta peptide (Aβ) and inhibit Aβ aggregation
and ﬁbril formation [5]. Deposition of Aβ aggregates and Aβ-containing
plaques in the brain is one of the hallmark pathological features of
Alzheimer disease (AD) [6]. Pre-clinical studies have shown that SI ame-
liorates AD-like pathology in the TgCRND8mousemodel of AD including
decreases in brain Aβ levels, plaque deposition and improvement of cog-
nitive deﬁcits [7,8]. Phase 2 clinical trials, in which SI was used to treat
patients withmild ormoderate AD, have recently been published: in pa-
tients with mild AD, treatment with 250 mg SI bid has shown cognitive
beneﬁt [9]. The continuing exploration of the therapeutic promises of SIino-4-methyl-coumarin; AMPA,
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12 Published by Elsevier B.V. All rigfacilitates the need for further investigation on the interaction of SI with
underlying mechanisms of the disease.
Another prominent feature of AD is the accumulation of autophagic
vacuoles (AVs) in neurons suggesting dysfunction in this degradation
pathway [10]. Autophagy is a cellular process inwhich intracellular com-
ponents are ‘self-digested’, degraded, and recycled via the lysosome [10].
Formation of AVs is a result of macroautophagy (hereafter referred to as
autophagy), a type of autophagy that degrades large-scale cellular con-
tents such as organelles and accounts for the majority of all autophagic
processes [10]. Initiation of autophagy involves signaling from various
pathways, which then induce the formation of a cup-like isolationmem-
brane that sequesters a region of cytoplasm; closure of the ‘cup’ results in
a double-membrane autophagosome that eventually fuseswith the lyso-
some [10,11]. The autophagic process acts as a protective mechanism to
conserve energy when a cell is under metabolic or other forms of stress
[11]. Autophagy is normally efﬁcient in the brain as reﬂected by the
lownumber of brain AVs at any givenmoment [12,13]. In contrast, brains
of ADpatients, aswell as, transgenicmouseADmodels exhibit prominent
accumulation of AVs in association with dystrophic neurites and de-
formed synaptic membranes [14,15]. Although autophagic defects are
also present in other neurodegenerative diseases, the extensive accumu-
lation of AVs in AD is unique [10]. The ﬁnding that these AVs contain Aβ,
as well as, proteins responsible for generating Aβ suggest that Aβ accu-
mulation may be the cause of impaired clearance of AVs and the subse-
quent detrimental effects on overall neuronal health [15]. The precise
relationship between autophagy and Aβ accumulation remains complex
and unresolved. Targeting autophagy initiation at different stages of the
pathway in vitro has produced opposing effects on Aβ-induced cell
death [16,17]. In ADmouse models, the stimulation of lysosomal activityhts reserved.
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proved cognitive deﬁcits, implicating a role for the latter stages of
autophagy in the autophagic deﬁcits detected in AD [18].
With regard to the growing interest in the interplay between au-
tophagy and AD, we set out to investigate the role of an Aβ-targeting
molecule, SI, on existing pathological features of AD. We investigated
the effects of SI treatment on disease-bearing TgCRND8mice by examin-
ing the different stages of the autophagic pathway.
2. Materials and methods
2.1. Chemicals and antibodies
All chemicals were purchased from Sigma unless otherwise speciﬁed.
SI was purchased from Wako (#096-04163). Rabbit anti-LC3 (1:3000,
Novus Biologicals, #NB600-1384), mouse beclin-1 (1:1000, BD Biosci-
ences, #612112), rabbit anti-P70S6K (1:1000, Cell Signaling, #9202), rab-
bit anti-phospho-P70S6K (1:1000, Cell Signaling, #9205), rabbit anti-
cathepsin D (1:2000, Abcam, #ab75852), mouse anti-p62 (1:500, Novus
Biologicals, #H00008878-M01), mouse anti-GAPDH (1:5000, Meridian,
#H86504M), rat anti-LAMP-1 (1:250, BD Biosciences, #553792), rabbit
anti-LAMP-2 (1:250, Invitrogen, #51-2200), rabbit anti-rab7 (1:200,
Santa Cruz, #sc-10767), mouse anti-Aβ (clone 6E10, 1:1000, Signet,
#SIG-39320-500), mouse anti-amyloid precursor protein (APP, clone
22C11, Millipore, #MAB348SP) and horseradish-peroxidase (HRP)-
conjugated secondary antibodies (1:2000, Santa Cruz) were obtained
commercially. The ﬂuorogenic proteasome substrate carbobenzoxy-L-
leucyl-leucyl-leucine (z-LLL)-linked 7-amino-4-methyl-coumarin (AMC)
was purchased from Santa Cruz (#sc-3128).
2.2. Mice
Age-matched non-transgenic littermate mice and TgCRND8 mice
were maintained on an outbred C3H/C57BL6 background and kept on
a 12 hour (h) light/dark cycle with food and water ad libitum. TgCRND8
mice overexpress the human Swedish and Indiana mutations under the
control of a hamster prion protein promoter [19]. One group of TgCRND8
mice was administered SI ad libitum via drinkingwater at 10 mg/mL for
4 weeks starting at 12 weeks of age. All experiments were performed in
accordance with the guidelines set by the Canadian Council for Animal
Care and the University of Toronto.
2.3. Aβ oligomerization
Stable Aβ oligomers were prepared as previously described [20].
2.4. Electron microscopy (EM)
Brain tissues for EM were prepared as previously described [14].
Brieﬂy, tissues were perfused with 4% paraformaldehyde (PFA), then
post-ﬁxed in a 0.1 M cacodylate buffer containing 4% PFA, 2.5%
gluteraldehyde, 5% sucrose, and 250 μMcalcium chloride. Theywere fur-
ther rinsed in 0.5% uranyl acetate (2 h) and 2% osmium tetroxide (1 h)
before dehydration through a graded series of 30–100% ethanol and pro-
pylene oxide [15 minutes (min) each]. Dehydrated tissues were embed-
ded in epoxy resin and sectioned by an Ultracut E ultramicrotome
(Reichert, Depew, NY). The generated thin sections were mounted on
copper grids, stained with Reynold's lead citrate (15 min), and viewed
under an H-7000 electron microscope (Hitachi, Pleasanton, CA).
For quantitative analysis of AVs, 25 ﬁelds were randomly captured at
30,000×magniﬁcation. As previously described, vacuoles engulﬁng het-
erogeneous cellular contents and organelles (often forming multi-
membrane structures) were classiﬁed as AVs [15,21]. AV diameters
were measured using ImageJ. AVs with a diameter >400 nm were
grouped as large AVs, and AVs with a diameter 200–400 nm were
grouped as small AVs.2.5. Subcellular fractionation
Subcellular fractionation was performed based on buoyant density
values previously described [22]. Tissues were mechanically homoge-
nized in phosphate-buffered saline (PBS) containing 0.3 M sucrose.
The homogenate was centrifuged at 2000×g for 5 min to precipitate
the post-nuclear fraction. The supernatant,which containedmost organ-
elles, was collected and centrifuged at 13,000 g for 10 min. The pelleted
fraction was resuspended in 50% Nycodenz and layered with 25%, 22%,
19%, 11%, 7%, and 0% Nycodenz from bottom to top before ultracentrifu-
gation at 256,000 rpm for 6 h in a Beckman Optima L90 ultracentrifuge
(SW41 rotor). The 50/25 interface and the 25/22 interface are enriched
in mitochondria and lysosomes respectively. The 22/19 interface was
further fractionated by overlaying a 30–20–10% Percoll gradient (from
bottom to top), centrifuged at 256,000 rpm for 30 min. The 20/10 inter-
face from this centrifugation contained light AVs (LAVs) while heavy
AVs (HAVs) pelleted at the bottom of the tube.
2.6. Immunoblotting
Whole-cell or fractionated samples of tissue that were analyzed by
immunoblotting were lysed in cold lysis buffer containing 50 mM Tris,
1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM ethylene glycol
tetraacetic acid, 150 mM NaCl, 0.8% Triton, 0.2% sodium dodecyl sulfate
(SDS), and 1 mM phenylmethanesulfonylﬂuoride. The lysates were
boiled in β-mercaptoethanol-containing lithium dodecyl sulfate sample
buffer (Invitrogen), subjected to electrophoresis in 12% bis–Tris gels,
and transferred to polyvinylidene ﬂuoride membranes using iBlot
(Invitrogen). For blotting, the membranes were blocked with 10% milk
in Tris-buffered saline (TBS) with 0.1% Tween (TBS-T) for 1 h, followed
by incubation in a primary antibody solution (containing 5% milk in
TBS-T) overnight in the cold room and HRP-conjugated secondary anti-
body solution (containing 5% milk in TBS-T) for 1 h. After treatment
with ECL prime (GE Life Sciences), the bands were visualized upon ﬁlm
exposure. The scanned protein bands were quantiﬁed using ImageJ and
normalized to either GAPDH or Ponceau S.
Ponceau S stainingwhen applicablewas performed prior to blocking.
Membranes were incubated in 0.1% Ponceau S (in 5% acetic acid) for
20 min followed by two 10 min washes with 5% acetic acid and two
10 min washes with water.
2.7. Enzyme assays
All enzymatic assays were performed with lysed samples of sub-
cellular fractions, as described above.
Cathepsin B catalytic activitywasmeasured using a speciﬁc substrate
carbobenzoxy-L-arginyl-arginine (z-R-R) which does not cross-react
with other cathepsins [23], linked toAMC. Based onpreviously described
methods [24], 50 μL of lysed samples was pre-incubated with L-cysteine
(ﬁnal concentration 4 mM) for 10 min at 37 °C. The reactionwas initiat-
ed by adding equal volume of the reaction buffer (ﬁnal concentrations
50 μMz-R-R-AMC, 400 μMsodiumacetate pH5.5). After 30 min incuba-
tion at 37 °C, AMC release indicating substrate cleavage was measured
on aﬂuorescenceplate reader (TECAN Inﬁnite 200) at 380 nmexcitation
and 460 nm emission.
Non-speciﬁc proteolytic activity was measured using casein linked
to ﬂuorescein (FITC) [25]. Casein-FITC was diluted to a ﬁnal concen-
tration of 10 μg/mL and incubated with 50 μL of samples (diluted in
PBS) for 30 min at 37 °C. FITC release indicating substrate cleavage
was measured on the aforementioned reader at 494 nm excitation
and 518 nm emission.
Proteosome activitywasmeasured using theﬂuorogenic proteasome
substrate z-LLL-AMC as previously described [26]. 50 μL of samples di-
luted in PBS was incubated for 2 h with 50 μL of 200 μM z-LLL-AMC at
37 °C. AMC release indicative of proteasome-mediated cleavage was
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citation and 460 emission.
All enzyme assays were normalized to total proteinwhichwasmea-
sured by the bicinchoninic acid protein assay kit (Thermo) according to
the manufacturer protocol.
2.8. Statistical analyses
Signiﬁcance levels were measured by Student's t-test and analysis
of variance (ANOVA) followed by Newman–Keuls post hoc. * and #
denote pb0.05.
3. Results
3.1. SI decreased the size and number of AVs in TgCRND8 mice
Previous studies have observed signiﬁcant AD pathology in TgCRND8
mice as early as 12 weeks of age and that SI treatment from 12 to
16 weeks of age alleviates the existing pathology [7,8]. We, therefore,
used the same age and treatment time to investigate potential changes
in the autophagic pathway. As previously reported [15,18], brain regions
with high Aβ load [19], such as cortex and hippocampus, were ﬁlled
with large AVs often showing a dense shade under electronmicrographs
(Fig. 1A). Many of these AVs contained remnants of organelles andwere
associated with dystrophic neurites as previously reported [15,18].
Quantitative analyses of EM micrographs showed that SI treatment sig-
niﬁcantly reduced the number of AVs in TgCRND8mice albeit still signif-
icantly higher than non-transgenic (Non-Tg)mice (Fig. 1A, B). This latter
ﬁnding is not surprising since amyloid precursor protein (APP) is
overexpressed by ﬁve-fold in the TgCRND8 mice and requires continual
turnover [19]. More speciﬁcally, the number of large AVs was increased
in untreated TgCRND8 mice and attenuated by SI treatment (Fig. 1C),
while the number of small AVs did not signiﬁcantly vary between the
three groups (Fig. 1D). AV size, as measured by vesicle diameter, in
untreated TgCRND8 mice also signiﬁcantly increased compared to
non-Tg mice and similarly was attenuated with SI treatment (Fig. 1E).
To corroborate the ﬁndings from morphological analyses, we used
immunoblotting to quantitatively examine the expression of several
autophagic markers in whole-cell hippocampal preparations. The in-
crease in the size and number of AVs in TgCRND8 mice may stem from
changes in various stages of the autophagic pathway. Over-stimulation
of autophagosome formation, impaired fusion of AVs and lysosomes,
or loss of proteolytic activity in lysosomes could all result in AV buildup.
To determine whether induction of autophagy was affected, we exam-
ined LC3 conversion, mammalian target of rapamycin (mTOR) activity
and beclin-1 expression (Fig. 2). The ratio of LC3-II:LC3-I is a commonly
used indicator of autophagosome formation. As more autophagosomes
form, the soluble LC3-I protein is converted to the lipid-bound LC3-II as-
sociated with autophagosomes [10,11]. We found that this conversion
was signiﬁcantly increased in untreated TgCRND8 mice compared to
non-Tg mice and signiﬁcantly ameliorated with SI treatment (Fig. 2A,
B). mTOR is a constitutive suppressor of autophagy induction; inhibition
of mTOR activity by either nutrient starvation or rapamycin leads to
autophagy initiation [27]. Beclin-1 is part of a kinase complex responsi-
ble for nucleation of the cup-like isolationmembrane [27].Wemeasured
mTOR activity by examining changes in the phosphorylation state of the
mTOR-speciﬁc substrate P70S6K [28]. We found that the level of phos-
phorylation of P70S6K did not vary between the three groups (Fig. 2A,
C). The level of beclin-1 expression also did not vary (Fig. 2A, D). These
results suggest that early modulators of autophagic induction including
mTOR and beclin-1 are not likely responsible for the observed accumu-
lation of AVs in TgCRND8 hippocampi. While increased LC3 conversion
could stem from over-induction of autophagy, it may also be a product
of reduced autophagic turnover and defects in the latter stages of the
autophagic pathway. To examine autophagic turnover, we analyzed
the expression of cathepsin D and p62, two indicators of autophagicturnover; cathepsin D is a lysosomal protease indicative of AV digestion
while p62 is involved in the targeting of ubiquitinated proteins to AVs
and is degraded upon turnover of AVs [29–31]. We found that conver-
sion of pro-cathepsin D to the smaller active form was upregulated in
untreated TgCRND8 mice and ameliorated with SI treatment (Fig. 2E,
F). p62 showed similar changes (Fig. 2E, G). These results corroborate
with the EM ﬁndings and point toward dysfunctional changes in the
overall state of autophagy in the TgCRND8 mice.
3.2. SI attenuates functional impairment in the late stages of autophagy
To better characterize the changes in the autophagic pathway, we
separated the tissue into fractions enriched with different autophagic
components. The light AV fraction (LAV) contained AVs in the earlier
stages of autophagosome maturation, marked by low levels of LC3-II
and LAMP-1, a lysosomal membrane protein [32] (Fig. 3A, B, C). The
heavy AV fraction (HAV) contained AVs in the late stages ofmaturation,
some of which have undergone AV-lysosomal fusion, marked by high
level of LC3-II and low level of LAMP-1 (Fig. 3A, B, C). The lysosomal
fraction contained the highest level of LAMP-1 and a moderate level of
LC3-II (Fig. 3A, B, C). In TgCRND8 mice, LC3-I to LC3-II conversion in-
creased in the LAV fraction compared to non-Tg mice, an effect attenu-
ated by SI treatment (Fig. 3A, B). Similar changes occurred in the
lysosomal fraction but not in the HAV fraction (Fig. 3A, B). The buildup
of LC3-II in the lysosomal fraction could result from insufﬁcient degra-
dation, while increased expression of LC3-II in the LAV may represent
‘backed-up’ autophagosomes unable to proceed toward AV-lysosome
fusion.
In order to try to correlate autophagic dysfunction with the presence
of Aβ, we usedWestern blot analyses to quantify the amount of Aβwith-
in each fraction. Immunoblot with the 6E10 antibody revealed that in
the untreated TgCRND8 mice, Aβ accumulated in the LAV, HAV, and ly-
sosomal fractions (Fig. 4A, B). The amount of Aβ accumulation increased
along the progression of the autophagic pathway, reaching the highest
level in the lysosomes of untreated TgCRND8 mice (Fig. 4A, B). SI treat-
ment prevented the accumulation of Aβ within all three fractions
(Fig. 4A, B). These results suggest that SI binding to Aβ allows for normal
transition through the autophagic pathway and efﬁcient degradation. To
verify that the observed SI-induced changes in Aβ did not result from al-
tered expression of Aβ precursors, we measured the levels of APP and
APP-β-C-terminal fragment (β-CTF) in the whole-cell homogenates.
APP is cleaved by β-secretase to yield β-CTF, which is subsequently
cleaved by γ-secretase generating monomeric Aβ [33]. We found that
while SI treatment decreased Aβ, it did not affect the expression of
APP and of β-CTF conﬁrming the lack of SI effect on APP expression
and proteolysis [7] (Fig. 4C–E).
SI treatment may also alter the degradation route of Aβ resulting in
lower Aβ load in the autophagic pathway and subsequent beneﬁt to
the autophagic pathway. To determine if thiswas the case, wemeasured
the proteolytic activity of proteasomes, anothermajor degradation path-
way that complements autophagy [34], which has been shown to be di-
rectly inhibited by Aβ [35]. We found that proteasome activity was
decreased in untreated TgCRND8 whole cell hippocampi lysates and
this inhibition was reversed in SI-treated TgCRND8 mice (Fig. 4G). The
increase in proteosome activity may be a direct effect of SI targeting
Aβ inhibition of proteosomal activity or a downstream effect of im-
proved neuronal function as a result of autophagic recovery. The inter-
dependence and complementary function of the proteosomal and
autophagic pathways does not allow for distinction between these two
events.
The ﬁnding that the majority of Aβ in the autophagic pathway accu-
mulated in lysosomes suggested that loss of lysosomal functionmight be
the cause of AV buildup in untreated TgCRND8 mice. We examined the
localization and expression of LAMP-1 and LAMP-2, proteins associated
with lysosomal and autophagosomal membranes that participate in
AV-lysosome fusion [32]. Both proteins were increased in untreated
Fig. 1. (A) Representative electron micrographs of hippocampal sections showing differences between non-transgenic (non-Tg), untreated TgCRND8 (un-Tg) and SI-treated
Tg-CRND8 (SI-Tg) mice with regard to prevalence and size of AVs (marked by triangular pointers). Scale bar at top left=500 nm. (B–E) Quantitative analyses of electron micro-
graphs. For each hippocampal sample, 25 ﬁelds at 30,000× magniﬁcation were randomly sampled and analyzed. AVs with a diameter>400 nm were grouped as large AVs, and
AVs with a diameter 200–400 nm were grouped as small AVs. * denotes pb0.05 (n=6). (B) Number of large AVs per ﬁeld. (C) Sum of small and large AVs per ﬁeld. (D) Number
of small AVs per ﬁeld. (E) Mean AV diameter in nm.
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LAMP-2 was elevated in the LAV fraction (Fig. 3A, C, D). Increased accu-
mulation of LAMP-1 and LAMP-2may reﬂect compensatorymechanisms
to counter impaired AV-lysosome fusion. However, LAMP-1 and LAMP-2levels were comparable between SI-treated and untreated TgCRND8
mice (Fig. 3A, C, D), suggesting that the increased levels may not be a
consequence of Aβ accumulation but a result of cellular changes resulting
from APP overexpression and/or mutations. Another protein involved in
Fig. 2. Expression of LC3 and markers of autophagic turnover is altered while expression of early-stage modulators of autophagy is not different between untreated and SI-treated
TgCRND8 mice. * denotes pb0.05 (n=6). Each n represents one whole homogenized hippocampus dissected from a PBS-perfused brain. (A) Representative immunoblots of LC3,
beclin-1, P-P70S6K, P70S6K, and GAPDH. (B) Densitometric quantiﬁcation of LC3-I to LC3-II conversion, (C) ratio of phospho/total P70S6K, and (D) beclin-1 (normalized to GAPDH).
(E) Representative immunoblots of cathepsin D (CatD), p62, and GAPDH. (F) Densitometric quantiﬁcation of pro-CatD to active-CatD conversion, and (G) p62 (normalized to
GAPDH).
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associates with endosomes, AVs, and lysosomes [36]. Late AVs, due to
fusion with endosomes, normally express the highest level of rab7 [37],
however, in the untreated TgCRND8 mice, rab7 expression was several
fold higher in the lysosomal fraction compared to non-Tg mice. Further-
more, rab7 levels were also increased in the LAV fraction (Fig. 3A, E);
these changeswere attenuatedwith SI treatment (Fig. 3A, E), implicating
an Aβ-dependent effect. Accumulation of rab7 in the lysosomes impli-
cates either compensatory mechanism for insufﬁcient AV-lysosome fu-
sion or overload of AV-derived content in the lysosomes from lack of
degradation.
To investigate the degradation rate of lysosomes, we examined the
proteolytic activity of cathepsin B, a protease involved in Aβ clearance
[38]. We measured cathepsin B activity in lysed fractions of LAV, HAV,
and lysosomes and found that compared to non-Tgmice, cathepsin B ac-
tivity in the untreated TgCRND8mice signiﬁcantly increased in the lyso-
somal fractions coupled with signiﬁcant decreased activity in the HAVfraction (Fig. 5A). Decreased activity in the HAV fraction may reﬂect im-
paired AV-lysosome fusion. SI treatment in the TgCRND8 mice signiﬁ-
cantly decreased lysosomal and increased HAV cathepsin B activity
(Fig. 5A). The total activity of cathepsin B in the three fractions was in-
creased in untreated TgCRND8 mice compared to non-Tg mice and at-
tenuated with SI treatment (Fig. 5B). These results are somewhat
surprising since increasedproteolytic activity is proposed to be associated
with efﬁcient degradation [10]. It is possible that an accumulation of Aβ
within the AV-lysosomal compartments in a state inaccessible for degra-
dation may hinder downregulator signals of enzymatic activity. To con-
ﬁrm the activity ﬁndings, we analyzed the pro- to active cathepsin B
conversion, which is also indicative of cathepsin B activity. Compared to
the activity assays, the active:pro-cathepsin B ratio showed similar
changes in treated and untreated TgCRND8 mice in the Lys fraction
(Fig. 5C, D). Active cathepsin B protein levelswere below the quantiﬁable
detection limit in the LAV and HAV fractions (Fig. 5C, D). We examined
the activity of non-speciﬁc proteases and observed similar results to
Fig. 3. Subcellular fractionation into LAV-, HAV-, and Lys-enriched fractions showing the expression of Aβ and proteins involved in AV-lysosome fusion. Cortices from 6 animals
were pooled for fractionation and repeated in 3 experiments (n=3). * denotes pb0.05 between different treatments; # denotes pb0.05 relative to the non-Tg group of the Lys
fraction. (A) Representative immunoblots of LC3, LAMP-1, LAMP-2, and rab7. (B) Densitometric quantiﬁcation of LC3-I to LC3-II conversion, (C) LAMP-1 (normalized to Ponceau
S), (D) LAMP-2 (normalized to Ponceau S), and (E) rab7 (normalized to Ponceau S).
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untreated TgCRND8 mice in all three fractions and attenuated with SI
treatment (Fig. 5E, F). It is interesting that SI treatment altered non-
speciﬁc protease activity in addition to cathepsin B activity, suggesting
that Aβ accumulation activates Aβ-degrading proteases, as well as
other proteolytic enzymes. Furthermore, subcellular fractions were
obtained from whole tissue including both neurons and glial cells, the
latter may not have the same autophagic dysfunction as neurons. In ad-
dition, glial cells uptake Aβ for degradation [39–41] which may lead to
glial activation and upregulation of proteases, some of which may ex-
hibit higher activities in the non-speciﬁc protease assay compared to ca-
thepsin B. We propose that Aβ accumulation in AVs and lysosomes
generates an unfavorable environment for protein degradation, causing
over-compensation and up-regulation of protease activity in general.
Increased cathepsin B activity may result from either generation of
more active proteases from pro-enzymes or increased recruitment
from other cellular compartments. In order to investigate the source of
increased cathepsin B, we incubated intact non-solublized lysosomal
fractions with Aβ oligomers and showed that both cathepsin B activity
and pro- to active cathepsin B conversion was increased (Fig. 5G, H, I).
These results suggest that increased cathepsin B activity is generated
from pro-enzymes rather than recruitment from other cellular compart-
ments or new protein synthesis. Furthermore, we found that the in-
creased cathepsin B activity as a result of oligomeric Aβ treatment was
ameliorated after co-treatment with SI (Fig. 5G, H, I).4. Discussion
The results presented in this study demonstrate that SI treatment
and subsequent binding to Aβ in vivo after disease onset can ameliorate
autophagic defects in the TgCRND8 mouse model for AD. In TgCRND8
mice, autophagy is mainly defective in the latter stages where AV-
lysosome fusion and lysosomal proteolysis occur. We showed that dys-
function in these processes can be rescued by SI. We also demonstrated
that attenuation of autophagic deﬁciencies by SI targeting Aβ correlated
with less AV accumulation.
The implications of this study are two-fold.With regard to the clinical
development of SI for the treatment of AD, this study provides a cellular
mechanism of action bywhich SI–Aβ interactionsmay exert some of the
therapeutic effects. There is strong evidence that autophagic defectsmay
be an underlying cause of sporadic AD [10]. A recent report showed that
inhibition of lysosomal proteolysis induces disruption in cellular trans-
port and subsequently AD-like pathology in non-transgenic neuronal
cultures [42]. Alternatively, stimulating lysosomal proteolysis from
birth, prevented the AD-like symptoms in TgCRND8 mice [18]. These
ﬁndings suggest that defective clearance of AVs can induce AD-like pa-
thology. Our results complement these studies by examining the effects
of an Aβ targeting treatment, SI, once AD-like pathology and autophagic
dysfunction is already present. Similar to the prevention study, we dem-
onstrate that reduction of Aβ in vivo is correlated with improved auto-
phagic function.
Fig. 4. (A–B) Representative immunoblots of LAV, HAV, and Lys fractions probed with the 6E10 antibody showing both APP and Aβ. Densitometric quantiﬁcation was performed on
Aβ (normalized to Ponceau S). Aβ levels increase as autophagy progresses reaching the highest level in the Lys fraction whereas SI treatment decreases Aβ levels in all three frac-
tions. Cortices from 3 animals were pooled for fractionation and repeated in 3 experiments (n=3). * denotes pb0.05 between different treatments. (C–F) Whole-cell cortical lysates
probed with either anti-APP (22C11 antibody) or 6E10 antibody. Whole-cell levels of APP and β-CTF did not vary while Aβ level decreased with SI treatment. * denotes pb0.05 (n=
3). Each n represents one whole homogenized cortex dissected from a PBS-perfused brain. (C) Representative immunoblots of APP, β-CTF, Aβ, and GAPDH. Densitometric quanti-
ﬁcations of (D) APP (normalized to GAPDH), (E) β-CTF (normalized to GAPDH), and (F) Aβ (normalized to GAPDH). (G) Proteasome activity in whole-cell cortical lysates. * denotes
pb0.05 (n=6). Each n represents one whole homogenized cortex dissected from a PBS-perfused brain.
1635A.Y. Lai, J. McLaurin / Biochimica et Biophysica Acta 1822 (2012) 1629–1637There are several challenges associated with interpretation of results
from transgenic mouse models of AD. One challenge is the presence of
compensatory mechanisms utilized by whole organisms to overcome
stressors. In the TgCRND8mousemodel early compensatorymechanisms
such as an increase in brain-derived neurotrophic factor and mitochon-
drial activity have been reported in early stages of AD-like pathology,
however, these were not maintained as disease progresses [43,44]. We
report an increase in cathepsin B and cathepsin D activities in untreated
TgCRND8mice at 4 months of age in comparison to non-transgenic litter-
mates that may represent an early yet ineffective attempt tomaintain Aβ
clearance. In support of this hypothesis, Yang and colleagues [18] showed
a decrease in cathepsin B, D and L activity in TgCRND8 mice at 6 months
of age in comparison to non-transgenic littermates, which represents an
established AD-like disease pathology. Lastly, this correlation must beconsidered in light of the different genetic backgrounds, C3H/C57bl6 ver-
sus 129, of this mouse model and potential confounds that this might
present [45].
Another challenge in interpreting results from AD mouse models is
distinguishing effects stemming from Aβ accumulation versus those
resulting from APP overexpression or mutations. In our study, we attri-
bute changes in autophagic proteins to Aβ accumulation as opposed to
transgene effects or holoprotein levels. The role of cathepsin B is particu-
larly intriguing.While cathepsin Bhas the capability to promoteAβ clear-
ance, it also facilitates cleavage of APP resulting in increased Aβ
deposition [38]. Previous ﬁndings [46,47] as well as our data found in-
creased cathepsin B in response to Aβ, which may aid Aβ degradation
but could also lead to increased cleavage of APP culminating in a vicious
cycle of Aβ production. This may also help to explain the observed
Fig. 5. Lysosomal cathepsin B (CatB) activity is up-regulated in TgCRND8 mice and is attenuated by SI treatment. Fractions enriched in LAV, HAV, Lys were collected from 6 pooled
cortices and repeated in 3 experiments (n=3). Activity assays of CatB, non-speciﬁc proteases, and proteasomes were performed using lysed samples of either whole-cell homog-
enates or subcellular fractions. * denotes pb0.05 between different treatments; # denotes pb0.05 relative to the non-Tg group of the Lys fraction. (A) CatB activity in the different
fractions. (B) Total CatB activity in the three fractions. (C) Representative immunoblots of CatB in the different fractions. (D) Densitometric quantiﬁcations of pro-CatB to
active-CatB conversion. (E) Non-speciﬁc protease activity in the different fractions. (F) Total non-speciﬁc protease activity in the different fractions. (G–I) Effects of Aβ and SI on
CatB in an isolated intact Lys fraction. The Lys fraction was isolated intact (without lysis), treated with 1 μM oligomeric Aβ and 10 μM SI for 1 h, then lysed and subjected to im-
munoblotting or CatB activity assays. * denotes pb0.05 (n=6). (G) Representative immunoblots of CatB in the Aβ-treated Lys fraction. (H) Densitometric quantiﬁcations of
pro-CatB to active CatB conversion in the Aβ-treated Lys fraction. (I) CatB activity in the Aβ-treated Lys fraction.
1636 A.Y. Lai, J. McLaurin / Biochimica et Biophysica Acta 1822 (2012) 1629–1637increase in Aβ accumulation concurrent with increased cathepsin B ac-
tivity in the early stages of AD-like pathology in the TgCRND8 mouse
model. Our data in conjunction with previous ﬁndings would suggest
that impaired proteolysis is both a cause and a consequence of Aβ
accumulation.
In conclusion, SI targeting Aβ is an effective treatment to restore
autophagic function in the TgCRND8 model of AD. SI treatment de-
creased the size and number of accumulated AVs and ameliorated ab-
normalities in the latter stages of autophagy including AV-lysosomal
fusion and lysosomal proteolysis. These results provide a mechanism
of action by which SI exerts some of the therapeutic effects in vivo and
aids our understanding of the relationship between autophagy, Aβ,
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